Forerunner Medical (Shanghai) Co., Ltd.

Forerunner Medical specializes in the development and production of innovative minimally invasive medical devices, employing advanced technologies to enhance patient care across various medical fields. Founded in 2009 in Shanghai, China, Forerunner Medical (Shanghai) Co. , Ltd. focuses on creating minimally invasive medical solutions.

The CEO, Jay Qin, leads the company, which has successfully completed 4 funding deals, with the most recent being a Series B round on March 5, 2021, raising a total of RMB 100 million. The company has not undergone any significant pivots in its strategy. Forerunner Medical (Shanghai) Co. , Ltd.

specializes in the research and production of innovative minimally invasive medical devices, utilizing three core technology platforms: low-temperature plasma, radiofrequency ablation, and implants. These products address critical needs in five medical fields: sports medicine, minimally invasive spine surgery, otolaryngology, interventional oncology, and respiratory interventions. By providing advanced diagnostic and therapeutic solutions, the company serves a diverse client base, including hospitals and medical practitioners across Europe, Southeast Asia, and North America, with products designed to enhance patient safety and improve clinical outcomes. Forerunner Medical generates revenue through the sales of its medical devices, which include proprietary technologies tailored to specific medical applications.

Transactions are conducted primarily through B2B channels, where hospitals and medical institutions procure their devices for clinical use. The company’s flagship products have received NMPA registration and certifications such as CE and ISO13485 and are sold directly to healthcare providers. Their pricing reflects the specialized nature of their applications, catering specifically to healthcare professionals and institutions, supported by established distribution networks. In March 2021, Forerunner Medical (Shanghai) Co.

, Ltd. raised over RMB 100 million in Series B funding, led by Apricot Capital, to support its expansion initiatives. The company plans to introduce new products based on their core technologies aimed at enhancing minimally invasive procedures. Additionally, they are targeting expansion into new markets in Europe and North America by 2024.

The recent funding will be utilized to accelerate research and development efforts, ensuring timely launches of innovative solutions to meet growing market demands.